NORDIC BIOTECH GENERAL PARTNER ApS: Financial statements 2022
CVR: 26270367
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
NORDIC BIOTECH GENERAL PARTNER ApS (CVR 26270367) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 11,750 and a net result of DKK 3,878 compared with DKK 7,716 the year before. That is a decrease of 25.4% compared with the year before. Equity in the 2022 report amounted to DKK 933,545. The solvency ratio was 97.7%.
- Gross Profit
- DKK 11,750
- Profit/Loss
- DKK 3,878
- Equity
- DKK 933,545
- Total Assets
- DKK 955,171
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 12K | 4K | 934K | 0 |
| 2021 | - | 16K | 8K | 930K | 0 |
| 2020 | - | -765K | -784K | 922K | - |
| 2019 | - | 16K | 7K | 1.7M | - |
| 2018 | - | -417K | -421K | 1.7M | 0 |
Official annual report
Keep an eye on NORDIC BIOTECH GENERAL PARTNER ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
NORDIC BIOTECH GENERAL PARTNER ApS has published its annual report for 2021. Gross profit came to DKK 15,750, and the net result was DKK 7,716.
About NORDIC BIOTECH GENERAL PARTNER ApS
NORDIC BIOTECH GENERAL PARTNER ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is in liquidation. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS and C. HANSEN INVEST ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 163,699 and a net result of DKK 178,169 compared with DKK 67,346 the year before. Equity in the 2025 report amounted to DKK 1,214,065.